E Fund Management (Hong Kong) Co., Ltd. Hutchmed (China) LTD Transaction History

E Fund Management (Hong Kong) Co., Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	BUY	$8.59 - $20.77 $74,277 - $179,598	8,647 Added 17.22%	58,861 $744,000
Q1 2022 Apr 12, 2022	BUY	$15.52 - $35.65 $446,184 - $1.02 Million	28,749 Added 133.93%	50,214 $859,000
Q4 2021 Feb 07, 2022	BUY	$28.89 - $35.33 $83,376 - $101,962	2,886 Added 15.53%	21,465 $753,000
Q2 2021 Jul 27, 2021	SELL	$23.7 - $39.27 $14,409 - $23,876	-608 Reduced 3.17%	18,579 $730,000
Q1 2021 Apr 13, 2021	BUY	$27.01 - $36.8 $9,480 - $12,916	351 Added 1.86%	19,187 $542,000
Q3 2020 Oct 09, 2020	BUY	$25.8 - $34.61 $147,369 - $197,692	5,712 Added 43.52%	18,836 $608,000
Q1 2020 May 13, 2020	BUY	$15.19 - $29.51 $199,353 - $387,289	13,124 New	13,124 $234,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of E Fund Management (Hong Kong) Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management (Hong Kong) Co., Ltd. with notifications on news.